Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.66 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.62 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20481791 | 0.85 | SCN9A (0.60) | SCN9ASCN5AKDRFLT3LCK | |
| SCHEMBL20481781 | 0.82 | SCN9A (0.64) | SCN9ASCN5AKDRFLT3LCK | |
| SCHEMBL20481828 | 0.82 | SCN9A (0.64) | SCN9ASCN5AKDR | |
| SCHEMBL18096744 | 0.81 | SCN9A (0.58) | SCN9ASCN5A | |
| SCHEMBL18096615 | 0.80 | SCN9A (1.00) | SCN9ASCN5AKDRFLT3LCK | |
| SCHEMBL20481975 | 0.79 | SCN9A (0.53) | SCN9ASCN5ACDK8CDK19 | |
| SCHEMBL20481818 | 0.79 | SCN9A (0.61) | SCN9ASCN5AKDRCDK8CDK19 | |
| SCHEMBL18096591 | 0.79 | SCN9A (0.67) | SCN9ASCN5AKDRFLT3SSTR2 | |
| SCHEMBL18096675 | 0.78 | SCN9A (0.52) | SCN9ASCN5ACDK8CDK19 | |
| SCHEMBL20481795 | 0.77 | SCN9A (0.46) | SCN9ASCN5ASSTR2SSTR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | ALMIRALL, S.A. (ES) | 2019-01-08 | — | — | US | disclosed |
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | ALMIRALL, S.A. (ES) | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244626-A1 | AMINOINDAZOLE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, SCN1A, SCN3A | SCN9A 31/4885SCN5A 4/4885KDR 2730/4885 |
| US-10173985-B2 | Aminoindazole derivatives as sodium channel inhibitors | SCN1B, SCN1A, SCN3A | SCN9A 29/4885SCN5A 4/4885KDR 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.